Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants With Invasive Ventilator-dependent X-linked Myotubular Myopathy

NCT07052929 is registered in ClinicalTrials.gov with Astellas Gene Therapies as lead sponsor.

NCT NCT07052929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07052929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants With Invasive Ventilator-dependent X-linked Myotubular Myopathy
Lead sponsor
Astellas Gene Therapies
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 15, 2025
Completion date
October 31, 2027
Enrollment
9 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

x-linked myotubular myopathy